Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Merck & Company, Inc.
MRK
$132.81
Name : Merck & Company, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $327,409,270,784.00
EPSttm : 0.99
finviz dynamic chart for MRK
Merck & Company, Inc.
$132.81
3.61%
$4.97
MRK — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

1.08

Margin Of Safety %

13

Put/Call OI Ratio

0.82

EPS Next Q Diff

-0.36

EPS Last/This Y

-6.19

EPS This/Next Y

6.18

Price

132.81

Target Price

162.96

Analyst Recom

1.81

Performance Q

-12.99

Upside

-74.2%

Beta

0.15

Ticker: MRK




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-10-21MRK149.920.810.40481126
2026-10-22MRK147.240.770.33508509
2026-10-23MRK145.270.760.30539520
2026-10-26MRK140.590.780.77519445
2026-10-27MRK141.850.780.71522050
2026-10-28MRK141.50.790.93529042
2026-10-29MRK146.750.800.37535499
2026-10-30MRK149.570.760.44566755
2026-11-02MRK148.40.820.70515617
2026-11-03MRK144.690.820.53519609
2026-11-04MRK150.350.830.76522446
2026-11-05MRK146.910.820.49525261
2026-11-06MRK146.710.821.13529063
2026-11-09MRK148.730.830.47523584
2026-11-10MRK148.040.820.81526953
2026-11-11MRK147.190.820.41531345
2026-11-12MRK146.970.821.00534154
2026-11-13MRK147.750.820.86534282
2026-11-16MRK144.420.830.73524851
2026-11-17MRK143.410.830.47540208
2026-11-18MRK137.750.830.36542837
2026-11-19MRK132.720.821.91545726
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-10-21MRK148.31-19.021301.52.66
2026-10-22MRK147.29-19.020058.22.66
2026-10-23MRK145.28-19.020149.12.66
2026-10-26MRK140.61-18.819691.02.66
2026-10-27MRK141.83-19.020035.82.65
2026-10-28MRK141.13-19.019707.42.65
2026-10-29MRK146.32-19.020752.12.65
2026-10-30MRK148.81-4.420238.32.65
2026-11-02MRK148.49-4.421148.32.65
2026-11-03MRK144.67-11.220524.52.75
2026-11-04MRK150.37-12.821908.22.76
2026-11-05MRK146.89-12.819882.32.76
2026-11-06MRK146.90-13.820407.42.77
2026-11-09MRK148.72-13.820741.92.77
2026-11-10MRK147.99-13.820288.62.78
2026-11-11MRK147.20-13.820275.02.78
2026-11-12MRK146.93-13.820372.92.78
2026-11-13MRK147.81-13.820555.52.78
2026-11-16MRK144.35-13.819883.32.78
2026-11-17MRK143.41-13.820238.52.78
2026-11-18MRK137.79-13.819475.22.78
2026-11-19MRK132.81-14.419547.72.79
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-10-21MRK-8.470.431.15
2026-10-22MRK-8.470.431.15
2026-10-23MRK-8.470.431.15
2026-10-26MRK-8.470.021.15
2026-10-27MRK-8.470.021.09
2026-10-28MRK-8.470.021.09
2026-10-29MRK-8.470.021.09
2026-10-30MRK-8.470.021.09
2026-11-02MRK-8.470.021.09
2026-11-03MRK-8.470.021.09
2026-11-05MRK-8.470.021.09
2026-11-06MRK-8.470.021.09
2026-11-09MRK-8.470.161.09
2026-11-10MRK-8.470.161.09
2026-11-11MRK-8.470.161.08
2026-11-12MRK-8.470.161.08
2026-11-13MRK-8.470.161.08
2026-11-16MRK-8.47-0.121.08
2026-11-17MRK-10.41-0.121.08
2026-11-18MRK-10.41-0.121.08
2026-11-19MRK-10.41-0.121.08
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

2.49

Avg. EPS Est. Current Quarter

1.75

Avg. EPS Est. Next Quarter

2.13

Insider Transactions

-10.41

Institutional Transactions

-0.12

Beta

0.15

Average Sales Estimate Current Quarter

16283

Average Sales Estimate Next Quarter

16446

Fair Value

150.38

Quality Score

64

Growth Score

77

Sentiment Score

32

Actual DrawDown %

15.4

Max Drawdown 5-Year %

-43.4

Target Price

162.96

P/E

135.56

Forward P/E

14.91

PEG

4.44

P/S

4.87

P/B

7.29

P/Free Cash Flow

22.19

EPS

0.98

Average EPS Est. Cur. Y​

2.79

EPS Next Y. (Est.)

8.96

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.65

Relative Volume

1.31

Return on Equity vs Sector %

-21.1

Return on Equity vs Industry %

-29.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.13

EBIT Estimation

19547.7
◆ MRK Healthcare
$132.74
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
10/20
Pullback
13/25
Volume
3/15
Valuation
18/20
TP/AR
3/10
Options
1/10
RSI
31.9
Range 1M
3.6%
🚀
Momentum Growth
Ride accelerating trends
N/A
39 /100
WEAK
Momentum
14/25
Growth
13/30
Estimates
6/20
Inst/Vol
3/15
Options
3/10
EPS Yr
-69%
EPS NY
219.6%
52W%
60.8%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +76.7% upside
Quality
9/30
Valuation
18/30
Growth
12/25
Stability
3/10
LT Trend
1/5
Upside
+76.7%
Quality
64
MoS
13%
MRK — P/E HistoricalDrug Manufacturers - General
Merck & Company, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 73000
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
MRK

Latest News

—
Caricamento notizie per MRK…
stock quote shares MRK – Merck & Co., Inc. Stock Price stock today
news today MRK – Merck & Co., Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MRK – Merck & Co., Inc. yahoo finance google finance
stock history MRK – Merck & Co., Inc. invest stock market
stock prices MRK premarket after hours
ticker MRK fair value insiders trading